Laboratorios Farmaceuticos Rovi, S.A.
LABFFOTCHealthcare● Active
$90.61
+$0.00(+0.00%)
Market Cap$4.6B
P/E Ratio—
52W High$90.61
52W Low$90.61
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LABFF · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.14B | $0.18B | $0.22B | $0.26B | $0.18B |
| Depreciation & Amort. | $0.03B | $0.03B | $0.02B | $0.02B | $0.02B |
| Stock-Based Comp. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Change in Working Capital | ($0.01B) | $0.01B | ($0.03B) | ($0.06B) | ($0.06B) |
| Net Cash from Operations | $0.19B | $0.14B | $0.11B | $0.24B | $0.15B |
| Investing Activities | |||||
| Capital Expenditure | ($0.07B) | ($0.06B) | ($0.06B) | ($0.05B) | ($0.04B) |
| Purchases of Investments | ($0.00B) | $0.00B | $0.00B | ($0.01B) | $0.00B |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Investing | ($0.07B) | ($0.08B) | ($0.05B) | ($0.06B) | ($0.04B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.05B) | ($0.09B) | ($0.13B) | ($0.18B) | ($0.08B) |
| Dividends Paid | ($0.05B) | ($0.06B) | ($0.07B) | ($0.05B) | ($0.02B) |
| Debt Issued / Repaid | $0.00B | $0.05B | ($0.01B) | ($0.01B) | ($0.00B) |
| Net Cash from Financing | ($0.05B) | ($0.06B) | ($0.16B) | ($0.15B) | ($0.06B) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.12B | $0.08B | $0.06B | $0.19B | $0.11B |
| FCF Margin %(computed) | 16.16% | 9.96% | 7.00% | 22.77% | 16.73% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · EUR · B
Explore more Laboratorios Farmaceuticos Rovi, S.A. data
About Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Cash Flow Statement
Laboratorios Farmaceuticos Rovi, S.A. generated operating cash flow of $0.19B and free cash flow of $0.12B for 2025 — a FCF margin of 16.16%. Capital expenditure was ($0.07B).
Frequently asked questions
LABFF · 4 questionsLaboratorios Farmaceuticos Rovi, S.A. generated free cash flow of $0.12B for 2025, up 57.9% year-over-year.
LABFF free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10